Site navigation

Navigation

Colorectal cancer (metastatic) - bevacizumab & cetuximab

Bevacizumab and cetuximab for metastatic colorectal cancer

Status: History
Expected date of issue: January 2007
Wave: 10
Process: MTA
Topic area:
  • Cancer
  • Digestive system
 

NICE project team

Executive Lead: Peter Littlejohns
Technical Lead: Zoe Garrett
Communications manager: Phil Ranson
Project manager: Reetan Patel
Assessment group: School of Health & Related Research Sheffield
Top


 

Provisional schedule

Consultation on draft scope by stakeholders: February 2005
Information meeting with consultees: 17 June 2005
Closing date for invited submissions / evidence submission: 23 August 2005
Final scope published: April 2005
1st appraisal committee meeting: 10 May 2006
2nd appraisal committee meeting 04 July 2006
Top


 

Consultees and Commentators

Consultees Commentators (no right of appeal)

Manufacturers / Sponsors

  • Roche Products Ltd (bevacizumab)
  • Merck Pharmaceuticals (cetuximab)

Patient / Carer Groups

  • Beating Bowel Cancer
  • Cancer Voices
  • CancerBACUP
  • ColonCancer Concern
  • CORE (Digestive Disorders Foundation)
  • Long-term Medical Conditions Alliance
  • Lynn?s Bowel Cancer Campaign
  • Macmillan Cancer Relief
  • Marie Curie Cancer Care
  • National Cancer Alliance
  • National Council for Palliative Care
  • Teenage Cancer Trust
  • Tenovus Cancer Information Centre

Professional Groups

  • Association of Cancer Physicians
  • Association of Coloproctologists of Great Britain
  • British Oncology Pharmacy Association (BOPA)
  • British Psychosocial Oncology Society (BPOS)
  • Cancer Research UK
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians' Medical Oncology Joint Special Committee
  • Royal College of Radiologists
  • Royal Pharmaceutical Society

Others

  • Department of Health
  • East Hampshire PCT
  • East Leeds PCT
  • Welsh Assembly Government

General

  • British National Formulary
  • Medicines and Healthcare products Regulatory Agency (MHRA)
  • National Public Health Service for Wales
  • NHS Confederation
  • NHS Purchasing and Supplies Agency
  • NHS Quality Improvement Scotland

Comparator Manufacturers

  • Sanofi-Aventis (oxaliplatin)
  • Pfizer Ltd (irinotecan)
  • Bristol-Myers Squibb Pharmaceuticals Ltd (tegafur uracil)
  • Mayne Pharma plc (fluorouracil)
  • Medac UK (fluorouracil)

Assessment Team

  • National Coordinating Centre for Health Technology Assessment
  • School of Health & Related Research Sheffield

Associated Guideline Groups

  • National Collaborating Centre for Cancer

Associated Public Health Groups

  • None

Research Groups

  • Institute of Cancer Research
  • MRC Clinical Trials Unit
  • National Cancer Research Institute
  • National Cancer Research Network

Top


 

Project history

Date Update
17 August 2004 Topic summary published.
28 October 2004 Provisional schedule updated.
15 December 2004 Provisional schedule updated.
25 January 2005 Project manager updated.
6 May 2005 Final scope and matrix of consultees and commentators published.
27 May 2005 Provisional schedule updated.
11 August 2005 Project manager and consultees updated.
22 November 2005 Consultees & commentators updated.
23 November 2005 Consultees & commentators and schedule updated.
14 March 2006 Project Manager updated
14 November 2006 Project Manager and schedule updated
Top


 

Key documents

This page was last updated:   10 November 2006